MedPath

Brineura

These highlights do not include all the information needed to use BRINEURA safely and effectively. See full prescribing information for BRINEURA. BRINEURA (cerliponase alfa) injection, for intraventricular use Initial U.S. Approval: 2017

Approved
Approval ID

485ab3c5-0359-4878-872f-2fe1e7df4047

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 2, 2020

Manufacturers
FDA

BioMarin Pharmaceutical Inc.

DUNS: 079722386

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

cerliponase alfa

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code68135-811
Application NumberBLA761052
Product Classification
M
Marketing Category
C73585
G
Generic Name
cerliponase alfa
Product Specifications
Effective DateJuly 2, 2020
FDA Product Classification

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Brineura - FDA Drug Approval Details